First Patient Treated on Mevion's Next Generation Proton Therapy System
Mevion Medical Systems announces the treatment of the first patient in the world on the MEVION S250i Proton Therapy System® at MedStar Georgetown University Hospital in Washington, D.C.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005234/en/
The MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning at MedStar Georgetown University Hospital in Washington, D.C. (Photo: Business Wire)
“The launch of the HYPERSCAN system is a major milestone in the field of proton therapy. It is the realization of a vision to create the most clinically advanced and economically viable proton therapy system in the world making proton therapy accessible across the spectrum of healthcare providers,” said Joseph Jachinowski, CEO of Mevion Medical Systems. “Mevion has consistently pushed the field of proton therapy forward. We first changed proton therapy by introducing a new paradigm of economic, compact proton systems and now we are doing it again by deploying an advanced approach to pencil beam delivery. These achievements are the result of a team passionate about the impact proton therapy can have on patients’ lives.”
New Clinical Capabilities
Proton therapy is a precise form of radiation therapy that has the potential to reduce the amount of radiation exposure in some cancers. The Mevion system at MedStar Georgetown includes HYPERSCAN™ pencil beam scanning (PBS) which improves on existing proton scanning capabilities enabling clinicians to deliver conformal fields faster and with more precision than in the past.
The HYPERSCAN system utilizes a novel technology, the Adaptive Aperture™, a proton multi-leaf collimator (pMLC), to achieve sharp lateral dose gradients. Multi-leaf collimators are common to conventional radiation therapy and were a key enabling technology to make intensity modulated radiation therapy (IMRT) possible. Mevion’s Adaptive Aperture pMLC is unique to proton therapy. Designed to protect sensitive organs at every energy layer of the treatment, this new type of proton MLC enables a similar paradigm change in proton therapy.
Uptick in Global Adoption
In addition to MedStar Georgetown, the MEVION S250i™ system is under active installation at centers throughout the US and Europe. Two more HYPERSCAN centers will be treating patients by the end of 2018. An additional two centers are in the construction planning phase, both of which are instances of existing sites adding a second treatment room.
“We are excited to see the rapid adoption of Mevion’s HYPERSCAN technology,” said Yoel Bakas, senior vice president of sales for Mevion Medical Systems. “Proton therapy has long been viewed as economically unrealistic for most cancer centers. The uptick in proton projects and repeat customers speaks to the strength of the Mevion economic and clinical approach.”
Integration and Economics in Proton Therapy
At Medstar Georgetown, the proton system is integrated directly to the hospital as part of a renovation to the existing cancer center entrance. While other proton centers often have to be built as separate standalone facilities, the compact size of the Mevion system enables it to be integrated to existing radiation oncology departments. This can bring significant economic savings to these projects by enabling the centers to share existing support services and personnel throughout the hospital rather than duplicating them in a standalone facility.
Proton Therapy Symposium at ESTRO 37
Mevion will be hosting a luncheon symposium at the annual European Society for Radiotherapy and Oncology (ESTRO) in Barcelona Spain on Saturday April 21st. Attendees are invited to come learn more about HYPERSCAN pencil beam scanning and compact Mevion proton therapy systems. A panel of speakers will be discussing the implementation of these projects and the clinical experiences of the HYPERSCAN system.
About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with presence in Europe and China. For more information, please visit www.mevion.com.
Follow Mevion on Twitter: https://twitter.com/mevionmedical
Connect with Mevion on LinkedIn: https://www.linkedin.com/company/mevion-medical-systems
Melanie Benton, 978-540-1551
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13 | Pressemelding
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16 | Pressemelding
HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati